{"title": "Mistelfieber mit subkutan injizierten Mistelpr\u00e4paraten", "author": "Maurice Orange; Reiner Penter", "url": "https://www.anthromedics.org/DMS-20845-DE", "hostname": "anthromedics.org", "description": null, "sitename": "anthromedics.org", "date": "2017-05-01", "cleaned_text": "fever with sub cutaneously injected mistletoe preparations With higher than commonly used doses, mistletoe preparations elicit high fever when applied at the beginning of mistletoe treatment and are thought to have added therapeutic benefit. The hallmarks of this type of fever are presented and its therapeutic value discussed, focusing on practical application and its assumed optimal course in clinical practice. Lastly, the role of mistletoe fever in the treatment of cancer is discussed. [1] Selg P. Mensch Jonas WB, 2001;9:55-64. ](https://doi.org/10.1159/000049008) [8] cancer. In: Baronzio GF, Hager ED (eds). ](https://doi.org/10.1007/978-0-387-33441-7_21) Immunother 2001;50:391-6. [10] O'Regan B, Hirschberg C. CA: Institute of Noetic Sciences; 1993. [11] [ Whitrow HC, Fowler GAA, Bogato FH. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in C, Glover DW. Spontaneous regression: a hidden treasure buried in time. Med Hypotheses 2002;58(2):115-9. [Crossref] ](https://doi.org/10.1054/mehy.2001.1469) [14] Orange M. Mistletoe for Cancer Patients. A Dissertational Thesis Submitted for the Degree of Master of Science in Clinical Oncology. University of Birmingham, School of Cancer Sciences. 2010. [15] [Penter R. Der Injektionszeitpunkt und HB. The importance of the primary dosage in mistletoe therapy. In: Die Mistel in der following fever-inducing mistletoe treatment: two case in Health and Medicine 2012;1(1):18-25. [Crossref] ](https://doi.org/10.7453/gahmj.2012.1.1.006) [21] Shamaa S. Phase II study of Viscum Fraxini-2 advanced hepatocellular Keshta SA. of viscum fraxini-2 in advanced hepatocellular carcinoma: "}